亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

美罗华 医学 狼疮性肾炎 内科学 胃肠病学 临床终点 安慰剂 中性粒细胞减少症 不利影响 环磷酰胺 免疫学 随机对照试验 化疗 淋巴瘤 病理 疾病 替代医学
作者
Brad H. Rovin,Richard Furie,Kevin Latinis,R. John Looney,Fernando C. Fervenza,Jorge Sánchez‐Guerrero,Romeo Maciuca,David Zhang,Jay Garg,Paul Brunetta,Gerald B. Appel
出处
期刊:Arthritis & Rheumatism [Wiley]
卷期号:64 (4): 1215-1226 被引量:1282
标识
DOI:10.1002/art.34359
摘要

To evaluate the efficacy and safety of rituximab in a randomized, double-blind, placebo-controlled phase III trial in patients with lupus nephritis treated concomitantly with mycophenolate mofetil (MMF) and corticosteroids.Patients (n = 144) with class III or class IV lupus nephritis were randomized 1:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. The primary end point was renal response status at week 52.Rituximab depleted peripheral CD19+ B cells in 71 of 72 patients. The overall (complete and partial) renal response rates were 45.8% among the 72 patients receiving placebo and 56.9% among the 72 patients receiving rituximab (P = 0.18); partial responses accounted for most of the difference. The primary end point (superior response rate with rituximab) was not achieved. Eight placebo-treated patients and no rituximab-treated patients required cyclophosphamide rescue therapy through week 52. Statistically significant improvements in serum complement C3, C4, and anti-double-stranded DNA (anti-dsDNA) levels were observed among patients treated with rituximab. In both treatment groups, a reduction in anti-dsDNA levels greater than the median reduction was associated with reduced proteinuria. The rates of serious adverse events, including infections, were similar in both groups. Neutropenia, leukopenia, and hypotension occurred more frequently in the rituximab group.Although rituximab therapy led to more responders and greater reductions in anti-dsDNA and C3/C4 levels, it did not improve clinical outcomes after 1 year of treatment. The combination of rituximab with MMF and corticosteroids did not result in any new or unexpected safety signals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
scholar丨崔发布了新的文献求助10
8秒前
want_top_journal完成签到,获得积分10
24秒前
26秒前
scholar丨崔完成签到,获得积分10
31秒前
33秒前
36秒前
简单的沛蓝完成签到 ,获得积分10
38秒前
JIAN完成签到 ,获得积分10
41秒前
Jasper应助hxn采纳,获得30
42秒前
xxx完成签到,获得积分10
45秒前
51秒前
Green完成签到,获得积分10
53秒前
斐嘿嘿发布了新的文献求助10
54秒前
谢丹完成签到 ,获得积分10
55秒前
寒冷的完成签到,获得积分10
59秒前
文武完成签到 ,获得积分10
1分钟前
zlf完成签到,获得积分10
1分钟前
1分钟前
1分钟前
香蕉觅云应助科研通管家采纳,获得10
1分钟前
1分钟前
林宥嘉完成签到 ,获得积分10
1分钟前
老夫子完成签到,获得积分10
1分钟前
kenti2023完成签到 ,获得积分10
1分钟前
2分钟前
YYYCCCCC发布了新的文献求助10
2分钟前
2分钟前
11发布了新的文献求助10
2分钟前
CipherSage应助miles采纳,获得10
2分钟前
周游完成签到 ,获得积分10
2分钟前
2分钟前
2分钟前
huihongzeng发布了新的文献求助10
2分钟前
Judy完成签到 ,获得积分10
2分钟前
利物鸟贝拉完成签到,获得积分10
2分钟前
2分钟前
Esperanza完成签到,获得积分10
2分钟前
miles发布了新的文献求助10
2分钟前
2分钟前
鹿茸与共发布了新的文献求助10
2分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990020
求助须知:如何正确求助?哪些是违规求助? 3532077
关于积分的说明 11256276
捐赠科研通 3270943
什么是DOI,文献DOI怎么找? 1805139
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228